181 related articles for article (PubMed ID: 29467213)
1. Rare Variants in the
Eclov RJ; Kim MJ; Smith R; Ahituv N; Kroetz DL
Drug Metab Dispos; 2018 May; 46(5):636-642. PubMed ID: 29467213
[TBL] [Abstract][Full Text] [Related]
2. ABCG2 regulatory single-nucleotide polymorphisms alter in vivo enhancer activity and expression.
Eclov RJ; Kim MJ; Chhibber A; Smith RP; Ahituv N; Kroetz DL
Pharmacogenet Genomics; 2017 Dec; 27(12):454-463. PubMed ID: 28930109
[TBL] [Abstract][Full Text] [Related]
3. Expression of ABCG2 (BCRP) is regulated by Nrf2 in cancer cells that confers side population and chemoresistance phenotype.
Singh A; Wu H; Zhang P; Happel C; Ma J; Biswal S
Mol Cancer Ther; 2010 Aug; 9(8):2365-76. PubMed ID: 20682644
[TBL] [Abstract][Full Text] [Related]
4. In Vivo Hepatic Enhancer Elements in the Human ABCG2 Locus.
Eclov RJ; Kim MJ; Smith RP; Liang X; Ahituv N; Kroetz DL
Drug Metab Dispos; 2017 Feb; 45(2):208-215. PubMed ID: 27856528
[TBL] [Abstract][Full Text] [Related]
5. Identification of Functional Transcriptional Binding Sites within Chicken
Zhang Y; Huang J; Li X; Fang C; Wang L
Genes (Basel); 2020 Feb; 11(2):. PubMed ID: 32050731
[TBL] [Abstract][Full Text] [Related]
6. Gene and functional up-regulation of the BCRP/ABCG2 transporter in hepatocellular carcinoma.
Sukowati CH; Rosso N; Pascut D; Anfuso B; Torre G; Francalanci P; Crocè LS; Tiribelli C
BMC Gastroenterol; 2012 Nov; 12():160. PubMed ID: 23153066
[TBL] [Abstract][Full Text] [Related]
7. Characterization of the breast cancer resistance protein (BCRP/ABCG2) in clear cell renal cell carcinoma.
Reustle A; Fisel P; Renner O; Büttner F; Winter S; Rausch S; Kruck S; Nies AT; Hennenlotter J; Scharpf M; Fend F; Stenzl A; Bedke J; Schwab M; Schaeffeler E
Int J Cancer; 2018 Dec; 143(12):3181-3193. PubMed ID: 30070687
[TBL] [Abstract][Full Text] [Related]
8. Cellular expression and function of naturally occurring variants of the human ABCG2 multidrug transporter.
Zámbó B; Mózner O; Bartos Z; Török G; Várady G; Telbisz Á; Homolya L; Orbán TI; Sarkadi B
Cell Mol Life Sci; 2020 Jan; 77(2):365-378. PubMed ID: 31254042
[TBL] [Abstract][Full Text] [Related]
9. ABCG2 expression, function, and promoter methylation in human multiple myeloma.
Turner JG; Gump JL; Zhang C; Cook JM; Marchion D; Hazlehurst L; Munster P; Schell MJ; Dalton WS; Sullivan DM
Blood; 2006 Dec; 108(12):3881-9. PubMed ID: 16917002
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapeutic drug-induced ABCG2 promoter demethylation as a novel mechanism of acquired multidrug resistance.
Bram EE; Stark M; Raz S; Assaraf YG
Neoplasia; 2009 Dec; 11(12):1359-70. PubMed ID: 20019844
[TBL] [Abstract][Full Text] [Related]
11. Transmembrane Domain Single-Nucleotide Polymorphisms Impair Expression and Transport Activity of ABC Transporter ABCG2.
Sjöstedt N; van den Heuvel JJMW; Koenderink JB; Kidron H
Pharm Res; 2017 Aug; 34(8):1626-1636. PubMed ID: 28281205
[TBL] [Abstract][Full Text] [Related]
12. Transcription factors Sp1 and Sp3 regulate expression of human ABCG2 gene and chemoresistance phenotype.
Yang WJ; Song MJ; Park EY; Lee JJ; Park JH; Park K; Park JH; Kim HP
Mol Cells; 2013 Oct; 36(4):368-75. PubMed ID: 23996530
[TBL] [Abstract][Full Text] [Related]
13. Transcriptional modulation of BCRP gene to reverse multidrug resistance by toremifene in breast adenocarcinoma cells.
Zhang Y; Wang H; Wei L; Li G; Yu J; Gao Y; Gao P; Zhang X; Wei F; Yin D; Zhou G
Breast Cancer Res Treat; 2010 Oct; 123(3):679-89. PubMed ID: 19967559
[TBL] [Abstract][Full Text] [Related]
14. GPER mediates decreased chemosensitivity via regulation of ABCG2 expression and localization in tamoxifen-resistant breast cancer cells.
Yu T; Cheng H; Ding Z; Wang Z; Zhou L; Zhao P; Tan S; Xu X; Huang X; Liu M; Peng M; Qiu YA
Mol Cell Endocrinol; 2020 Apr; 506():110762. PubMed ID: 32087276
[TBL] [Abstract][Full Text] [Related]
15. Interindividual Regulation of the Breast Cancer Resistance Protein/
Bircsak KM; Moscovitz JE; Wen X; Archer F; Yuen PYS; Mohammed M; Memon N; Weinberger BI; Saba LM; Vetrano AM; Aleksunes LM
Drug Metab Dispos; 2018 May; 46(5):619-627. PubMed ID: 29386232
[TBL] [Abstract][Full Text] [Related]
16. BCRP/
Wen X; Kozlosky D; Zhang R; Doherty C; Buckley B; Barrett E; Aleksunes LM
Drug Metab Dispos; 2021 Aug; 49(8):629-637. PubMed ID: 34074729
[TBL] [Abstract][Full Text] [Related]
17. Correlation between the promoter methylation status of ATP-binding cassette sub-family G member 2 and drug sensitivity in colorectal cancer cell lines.
Moon HH; Kim SH; Ku JL
Oncol Rep; 2016 Jan; 35(1):298-306. PubMed ID: 26497773
[TBL] [Abstract][Full Text] [Related]
18. Functional cyclic AMP response element in the breast cancer resistance protein (BCRP/ABCG2) promoter modulates epidermal growth factor receptor pathway- or androgen withdrawal-mediated BCRP/ABCG2 transcription in human cancer cells.
Xie Y; Nakanishi T; Natarajan K; Safren L; Hamburger AW; Hussain A; Ross DD
Biochim Biophys Acta; 2015 Mar; 1849(3):317-27. PubMed ID: 25615818
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic modulation of the drug resistance genes MGMT, ABCB1 and ABCG2 in glioblastoma multiforme.
Oberstadt MC; Bien-Möller S; Weitmann K; Herzog S; Hentschel K; Rimmbach C; Vogelgesang S; Balz E; Fink M; Michael H; Zeden JP; Bruckmüller H; Werk AN; Cascorbi I; Hoffmann W; Rosskopf D; Schroeder HW; Kroemer HK
BMC Cancer; 2013 Dec; 13():617. PubMed ID: 24380367
[TBL] [Abstract][Full Text] [Related]
20. Drug resistance of bladder cancer cells through activation of ABCG2 by FOXM1.
Roh YG; Mun MH; Jeong MS; Kim WT; Lee SR; Chung JW; Kim SI; Kim TN; Nam JK; Leem SH
BMB Rep; 2018 Feb; 51(2):98-103. PubMed ID: 29397866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
